Hereditary Cancer Genetic Testing & Precision Medicine
CLIA-certified AI-powered genetic testing in Chicago, IL.
View Plans Browse Tests BRCA TestingFor Healthcare Providers
Your Complete Clinical Partner
CPT codes, sample clinical reports, verified ordering workflows, board-certified medical director oversight, and 24/7 genetic counselor support — everything your practice needs to deliver precision genetic medicine with confidence.
5,000+
Provider Partners
200K+
Tests Ordered
48 hrs
Avg Turnaround
CPT Codes & Billing Reference
20+ verified CPT codes with 2026 CMS/Medicare fee schedules and reimbursement estimates for oncology, PGx, and carrier screening panels.
View Full CPT TableMedical Director Oversight
Dr. Arjun Patel, MD PhD FACMG — CLIA Laboratory Director with 200+ publications and 19+ years in clinical genetics.
Meet Our Lab DirectorPhysician-Ready Sample Report
Annotated clinical reports with ACMG variant classification, drug-gene interaction alerts, and actionable physician recommendations.
Preview Report7-Step Ordering Workflow
From provider registration to AI-validated test submission — full EHR integration with HL7 FHIR, SSO, and real-time status tracking.
See Full WorkflowCLIA Certified Lab
CAP Accredited
ABMGG Board Certified
24/7 Genetic Counseling
EHL HL7 FHIR Ready
BILLING & REIMBURSEMENT
CPT Codes Reference Table
Complete billing code reference for genetic testing services. Pre-verified against CMS, commercial payer, and Medicare fee schedules for 2026.
CMS VerifiedMedicare 2026 ScheduleCommercial Payer Ready
| CPT Code | Description | Genes | Avg. Reimbursement | Category |
|---|---|---|---|---|
| 81432 | Hereditary breast cancer-related disorders (e.g., BRCA1, BRCA2) — full gene sequence analysis | 2 | $2,100 – $2,800 | Hereditary Cancer |
| 81433 | Hereditary breast cancer-related disorders — duplication/deletion analysis | 2 | $850 – $1,200 | Hereditary Cancer |
| 81445 | Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis — 5-50 genes | 50 | $1,400 – $2,200 | Hereditary Cancer |
| 81450 | Targeted genomic sequence analysis panel, hematolymphoid neoplasm — 5-50 genes | 50 | $1,400 – $2,200 | Hereditary Cancer |
| 81455 | Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm — >50 genes | 108 | $2,800 – $4,500 | Hereditary Cancer |
| 81479 | Unlisted molecular pathology procedure — custom panels, novel biomarkers, and research assays | 230 | Varies — submit for review | Pharmacogenomics |
| 81225 | CYP2C19 gene analysis — common variants (e.g., *2, *3, *17) for clopidogrel & PPI metabolism | 1 | $180 – $260 | Pharmacogenomics |
| 81226 | CYP2D6 gene analysis — common variants (*3-*6, *9, *10, *17, *41) for antidepressant & tamoxifen metabolism | 1 | $180 – $260 | Pharmacogenomics |
| 81227 | CYP2C9 gene analysis — common variants (*2, *3) for warfarin & NSAID sensitivity | 1 | $180 – $260 | Pharmacogenomics |
| 81230 | CYP3A4 gene analysis — common variant (*22) for statin & immunosuppressant metabolism | 1 | $160 – $240 | Pharmacogenomics |
| 81231 | CYP3A5 gene analysis — common variants (*3, *6, *7) for tacrolimus & chemotherapy metabolism | 1 | $160 – $240 | Pharmacogenomics |
| 81350 | SLCO1B1 gene analysis — common variant (*5) for simvastatin-induced myopathy risk | 1 | $160 – $240 | Pharmacogenomics |
| 81400 | Molecular pathology procedure, Level 1 — single analyte (e.g., VKORC1, F5, F2, MTHFR) | 1 | $120 – $180 | Pharmacogenomics |
| 81401 | Molecular pathology procedure, Level 2 — single analyte with common variants (e.g., HLA-B*57:01, TPMT, DPYD) | 1 | $140 – $200 | Pharmacogenomics |
| 81408 | Molecular pathology procedure, Level 9 — full gene sequence analysis (e.g., CFTR, DMD, HBA1/HBA2) | 1 | $900 – $1,400 | Comprehensive |
| 81442 | Noonan spectrum disorders gene analysis panel — 5-50 genes (PTPN11, SOS1, RAF1, KRAS, NRAS, BRAF, MAP2K1, SHOC2, CBL) | 9 | $1,200 – $1,800 | Pediatric / Inherited |
| 81443 | Genetic testing for severe inherited conditions (e.g., SMA, CF) — carrier screening panel | 3 | $600 – $950 | Pediatric / Inherited |
| 81228 | CYP2C19 gene analysis — full sequence (all exons) for rare variant detection | 1 | $450 – $650 | Pharmacogenomics |
| 81435 | Hereditary colon cancer disorders (e.g., Lynch syndrome) — 5-50 genes including MLH1, MSH2, MSH6, PMS2, EPCAM | 5 | $1,400 – $2,000 | Hereditary Cancer |
| 81437 | Hereditary colon cancer disorders — duplication/deletion analysis for Lynch syndrome genes | 5 | $700 – $1,100 | Hereditary Cancer |
81432Hereditary Cancer
Hereditary breast cancer-related disorders (e.g., BRCA1, BRCA2) — full gene sequence analysis
Genes: 2$2,100 – $2,800
81433Hereditary Cancer
Hereditary breast cancer-related disorders — duplication/deletion analysis
Genes: 2$850 – $1,200
81445Hereditary Cancer
Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis — 5-50 genes
Genes: 50$1,400 – $2,200
81450Hereditary Cancer
Targeted genomic sequence analysis panel, hematolymphoid neoplasm — 5-50 genes
Genes: 50$1,400 – $2,200
81455Hereditary Cancer
Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm — >50 genes
Genes: 108$2,800 – $4,500
81479Pharmacogenomics
Unlisted molecular pathology procedure — custom panels, novel biomarkers, and research assays
Genes: 230Varies — submit for review
81225Pharmacogenomics
CYP2C19 gene analysis — common variants (e.g., *2, *3, *17) for clopidogrel & PPI metabolism
Genes: 1$180 – $260
81226Pharmacogenomics
CYP2D6 gene analysis — common variants (*3-*6, *9, *10, *17, *41) for antidepressant & tamoxifen metabolism
Genes: 1$180 – $260
81227Pharmacogenomics
CYP2C9 gene analysis — common variants (*2, *3) for warfarin & NSAID sensitivity
Genes: 1$180 – $260
81230Pharmacogenomics
CYP3A4 gene analysis — common variant (*22) for statin & immunosuppressant metabolism
Genes: 1$160 – $240
81231Pharmacogenomics
CYP3A5 gene analysis — common variants (*3, *6, *7) for tacrolimus & chemotherapy metabolism
Genes: 1$160 – $240
81350Pharmacogenomics
SLCO1B1 gene analysis — common variant (*5) for simvastatin-induced myopathy risk
Genes: 1$160 – $240
81400Pharmacogenomics
Molecular pathology procedure, Level 1 — single analyte (e.g., VKORC1, F5, F2, MTHFR)
Genes: 1$120 – $180
81401Pharmacogenomics
Molecular pathology procedure, Level 2 — single analyte with common variants (e.g., HLA-B*57:01, TPMT, DPYD)
Genes: 1$140 – $200
81408Comprehensive
Molecular pathology procedure, Level 9 — full gene sequence analysis (e.g., CFTR, DMD, HBA1/HBA2)
Genes: 1$900 – $1,400
81442Pediatric / Inherited
Noonan spectrum disorders gene analysis panel — 5-50 genes (PTPN11, SOS1, RAF1, KRAS, NRAS, BRAF, MAP2K1, SHOC2, CBL)
Genes: 9$1,200 – $1,800
81443Pediatric / Inherited
Genetic testing for severe inherited conditions (e.g., SMA, CF) — carrier screening panel
Genes: 3$600 – $950
81228Pharmacogenomics
CYP2C19 gene analysis — full sequence (all exons) for rare variant detection
Genes: 1$450 – $650
81435Hereditary Cancer
Hereditary colon cancer disorders (e.g., Lynch syndrome) — 5-50 genes including MLH1, MSH2, MSH6, PMS2, EPCAM
Genes: 5$1,400 – $2,000
81437Hereditary Cancer
Hereditary colon cancer disorders — duplication/deletion analysis for Lynch syndrome genes
Genes: 5$700 – $1,100
Download Full CPT Codes + ICD-10 Crosswalk
Complete billing guide with modifier guidance, prior auth checklists, and payer-specific reimbursement rates. Updated monthly.
Reimbursement rates are estimates based on 2026 Medicare fee schedules and may vary by payer, region, and patient coverage. Always verify with your billing department.
ORDERING WORKFLOW
7-Step Provider Ordering Process
From provider registration to clinical report delivery — every step is optimized for speed, accuracy, and seamless EHR integration. Average turnaround: 48 hours.
48 hrs
Average TAT
200+
Orders / Hour
99.8%
Auto-Validation
24 hrs
Kit Delivery
STEP 01
Provider Registration
Complete the online partnership application with practice NPI, state license verification, and estimated monthly test volume. Our provider relations team reviews and approves within 1–2 business days.
NPI & state license verification
HIPAA Business Associate Agreement (BAA) executed
CLIA laboratory director co-signing protocols
Provider portal credentials issued
1–2 business days
STEP 02
EHR Integration Setup
Our integration engineers configure HL7 FHIR or direct API connections to your EHR system (Epic, Cerner, Athenahealth, eCW, Allscripts, or custom). Patient demographics, ICD-10 codes, and insurance data auto-populate on the first order.
2–4 hours
STEP 03
Place Test Order
Select the appropriate genetic test panel from our catalog of 10+ CLIA-certified assays. AI-powered clinical appropriateness checks validate ICD-10 coding, insurance pre-authorization status, and prior order history before submission.
< 60 seconds
STEP 04
AI Validation & Quality Review
Every order passes through our AI-driven validation pipeline: clinical appropriateness scoring, drug-gene interaction screening, insurance coverage verification, and patient eligibility confirmation. Flagged orders are escalated to our board-certified genetic counselors for review.
Real-time
STEP 05
Kit Shipped / Specimen Collected
For at-home saliva kits, the patient receives the DNA collection kit via overnight courier within 24 hours. For in-clinic blood draws, the specimen is shipped in a pre-labeled CLIA-compliant transport container with chain-of-custody tracking.
24–48 hours
STEP 06
Lab Processing & Analysis
Samples are processed in our CLIA-certified Chicago laboratory using Agena Bioscience MassArray MALDI-TOF mass spectrometry. Genotyping covers 230+ genes with 99.9% accuracy against Sanger sequencing reference standards. CAP proficiency testing passed every cycle.
36–48 hours from receipt
STEP 07
Physician-Ready Report Delivery
Board-certified medical director reviews variant classifications per ACMG/AMP guidelines. Reports are delivered to your EHR inbox, provider portal dashboard, and patient portal simultaneously. Genetic counseling referrals are auto-triggered for pathogenic findings.
48 hours total turnaround
STEP 01
1–2 business daysProvider Registration
Complete the online partnership application with practice NPI, state license verification, and estimated monthly test volume. Our provider relations team reviews and approves within 1–2 business days.
NPI & state license verification
HIPAA Business Associate Agreement (BAA) executed
CLIA laboratory director co-signing protocols
Provider portal credentials issued
STEP 02
2–4 hoursEHR Integration Setup
Our integration engineers configure HL7 FHIR or direct API connections to your EHR system (Epic, Cerner, Athenahealth, eCW, Allscripts, or custom). Patient demographics, ICD-10 codes, and insurance data auto-populate on the first order.
STEP 03
< 60 secondsPlace Test Order
Select the appropriate genetic test panel from our catalog of 10+ CLIA-certified assays. AI-powered clinical appropriateness checks validate ICD-10 coding, insurance pre-authorization status, and prior order history before submission.
STEP 04
Real-timeAI Validation & Quality Review
Every order passes through our AI-driven validation pipeline: clinical appropriateness scoring, drug-gene interaction screening, insurance coverage verification, and patient eligibility confirmation. Flagged orders are escalated to our board-certified genetic counselors for review.
STEP 05
24–48 hoursKit Shipped / Specimen Collected
For at-home saliva kits, the patient receives the DNA collection kit via overnight courier within 24 hours. For in-clinic blood draws, the specimen is shipped in a pre-labeled CLIA-compliant transport container with chain-of-custody tracking.
STEP 06
36–48 hours from receiptLab Processing & Analysis
Samples are processed in our CLIA-certified Chicago laboratory using Agena Bioscience MassArray MALDI-TOF mass spectrometry. Genotyping covers 230+ genes with 99.9% accuracy against Sanger sequencing reference standards. CAP proficiency testing passed every cycle.
STEP 07
48 hours total turnaroundPhysician-Ready Report Delivery
Board-certified medical director reviews variant classifications per ACMG/AMP guidelines. Reports are delivered to your EHR inbox, provider portal dashboard, and patient portal simultaneously. Genetic counseling referrals are auto-triggered for pathogenic findings.
CLINICAL OVERSIGHT
Medical Director & Laboratory Director
Clinical oversight, variant interpretation standards, and quality benchmarks are overseen by our board-certified Medical Director.
Active Laboratory Director
Dr. Arjun Patel
MD, PhD, FACMG
19+
Years in Clinical Genetics
200+
Peer-Reviewed Publications
15K+
Cases Supervised
FACMG
Board Certification
Dr. Arjun Patel, MD, PhD, FACMG
Medical Director & CLIA Laboratory Director, GeneMatrix AI
Dr. Arjun Patel is a board-certified medical geneticist and molecular pathologist with over 19 years of clinical and research experience in hereditary cancer syndromes, pharmacogenomics, and computational genomics. He serves as both the Medical Director and CLIA Laboratory Director for GeneMatrix AI, overseeing clinical interpretation protocols, variant classification standards, and CAP-accredited quality management systems for all laboratory operations at our Chicago, Illinois facility (CLIA ID: 14D2276402).
Before joining GeneMatrix, Dr. Patel served as Associate Professor of Human Genetics at Northwestern University Feinberg School of Medicine and directed the Hereditary Cancer Genomics Program at Northwestern Memorial Hospital. His clinical research has focused on multi-gene panel testing for hereditary breast and ovarian cancer, Lynch syndrome, and polygenic risk stratification — with over 200 peer-reviewed publications in journals including Nature Genetics, The Lancet, JAMA, and Journal of Clinical Oncology.
Dr. Patel leads GeneMatrix's Medical Advisory Board in establishing clinical reporting standards, establishing variant interpretation tiers, and validating AI-assisted genomic analysis pipelines. All clinical reports issued by GeneMatrix are reviewed under the oversight protocols he designed, ensuring that variant classifications meet ACMG/AMP classification guidelines and that clinical recommendations follow current NCCN, CPIC, and FDA pharmacogenomics guidelines.
He is a Fellow of the American College of Medical Genetics and Genomics (FACMG), a member of the American Society of Human Genetics (ASHG), and an active contributor to the Clinical Pharmacogenomics Implementation Consortium (CPIC). He holds dual board certification from the American Board of Medical Genetics and Genomics (Clinical Genetics) and the American Board of Internal Medicine.
Precision medicine only delivers on its promise when every genetic interpretation is grounded in rigorous evidence, transparent clinical reasoning, and the humility to acknowledge uncertainty. At GeneMatrix, we built a reporting standard that clinicians can trust — because patients deserve nothing less.
Dr. Arjun Patel, MD, PhD, FACMG
Medical Director, GeneMatrix AI
CLIA Certified Lab
CLIA ID: 14D2276402
CAP Accredited
College of American Pathologists
ABMGG Certified
American Board Med Genetics
SAMPLE REPORT
Physician-Ready Clinical Reports
Reports are structured for clinical workflows — clear variant classification, ACMG-tier ratings, actionable recommendations, and physician co-signature by our CLIA-certified lab director.
GeneMatrix AI — Clinical Genetics Report
CLIA: 14D2276402 · NPI: 1225729312 · CAP Accredited
FINAL REPORTCPT: 81455
Patient ID
PT-2025-44881
Accession
GM-2025-ACC-88123
Report Date
May 2, 2026
Ordered By
Dr. Kathleen Moore, MD
GeneCancer — 108-Gene Hereditary Cancer Panel
Ordered by: Dr. Kathleen Moore, MD — Northwestern Memorial Hospital
Gene Results — Selected Findings
GeneVariant / FindingClassification
BRCA1Pathogenic
c.5266dupC (p.Gln1756ProfsTer25)
Hereditary Breast/Ovarian Cancer
BRCA1Pathogenic
c.5266dupC (p.Gln1756ProfsTer25)
Hereditary Breast/Ovarian Cancer
BRCA2Negative
No pathogenic variant detected
—
BRCA2Negative
No pathogenic variant detected
TP53Negative
No pathogenic variant detected
—
TP53Negative
No pathogenic variant detected
MLH1Negative
No pathogenic variant detected
—
MLH1Negative
No pathogenic variant detected
PALB2Likely Pathogenic
c.1592delT (p.Leu531TrpfsTer7)
Hereditary Breast Cancer
PALB2Likely Pathogenic
c.1592delT (p.Leu531TrpfsTer7)
Hereditary Breast Cancer
Clinical Significance
Two clinically significant variants identified. BRCA1 c.5266dupC is a well-characterized pathogenic founder variant (5382insC) associated with significantly elevated lifetime risk for breast cancer (57–65%) and ovarian cancer (39–46%). PALB2 variant is classified as Likely Pathogenic per ACMG/AMP criteria.
Clinical Recommendations
- 1Refer to high-risk oncology breast program for intensive surveillance (annual MRI + mammography, starting immediately)
- 2Discuss risk-reducing surgery options (bilateral prophylactic mastectomy, bilateral salpingo-oophorectomy)
- 3Recommend cascade testing for first-degree relatives; BRCA1 mutation testing is recommended for all at-risk family members
- 4Refer to genetic counselor for comprehensive risk assessment, pedigree review, and familial counseling
- 5Consider platinum-based chemotherapy or PARP inhibitor therapy if cancer diagnosis is made — BRCA1 tumors show preferential response
Dr. Arjun Patel, MD, PhD, FACMG
Medical Director & CLIA Laboratory Director
Reviewed: May 3, 2026 · CLIA ID: 14D2276402
Digitally Signed & Validated
This report was generated and validated under CAP/CLIA-accredited quality management protocols. Variants are classified per ACMG/AMP 2015 guidelines. Drug-gene interactions follow CPIC Level A–B guidelines. All recommendations should be reviewed in the context of patient clinical history. This report does not constitute medical advice.
GET IN TOUCH
Start Your Provider Partnership
Complete the form below and our provider relations team will contact you within 1–2 business days with onboarding details, integration timelines, and a personalized contract proposal.
Provider Hotline
(847) 302-9668
Mon–Fri 8AM–5PM CT
Provider Relations Email
partnerships@genematrix.io
Average response: 4 hours
Clinical Laboratory
1375 W Fulton St STE 545
Chicago, IL 60607
Schedule a Demo
Book a 30-min demo call
With our clinical integration team
Why Providers Choose GeneMatrix
CLIA-certified laboratory with CAP accreditation
99.9% accuracy validated against Sanger sequencing
Average 48-hour turnaround time
Dedicated genetic counselor on every pathogenic case
EHR integration with 200+ systems supported
Cookie & Privacy Preferences
HIPAA GDPR
We use cookies to ensure our website functions securely and to improve your experience. As a healthcare provider handling sensitive genetic data, we adhere to strict HIPAA and GDPR standards. No personal health information (PHI) is ever stored in cookies. You can customize your preferences below.